Remove Events Remove Image Interpretation Remove Imaging Remove Radiation Oncology
article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Gauden , D.Phil., Chief Executive Officer of Blue Earth Diagnostics. Kuo, MD, Ph.D., Ulaner, MD, Ph.D.,

article thumbnail

Meet the Minnies 2024 semifinal candidates

AuntMinnie

The following is the list of candidates for the 2024 edition of the Minnies, AuntMinnie.com 's campaign to recognize the best and brightest in medical imaging. Image from Martin W. Image from Denis Le Bihan, PhD, of the NeuroSpin research facility, et al. Image from Richard Carson, PhD, of Yale University, et al.

article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. Gauden, D.Phil.